Fortune linked to India's second-largest drug maker, Dr. Reddy's Laboratories, which is shared by late founder K. Anji Reddy's son Satish Reddy and son-in-law G.V. Prasad, took a hit after a U.S. FDA inspection of 3 of its factories resulted in warnings from the regulator in November. The company, which gets more than 50% of its $2.3 billion in revenue from the U.S., has spent $36 million so far on fixing the problems. It has also been beefing up its portfolio with acquisitions: It bought 6 over-the-counter brands from U.S. drugmaker Ducere Pharma and completed the acquisition of 8 pipeline drugs from Teva Pharmaceuticals Industries and an affiliate of Ireland-based Allergan.